Cargando…

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies

SIMPLE SUMMARY: NK cells are innate immune cells that form one of the initial responses to infections and cancers. There have been increasing number of studies investigating the anti-tumor effects of NK cells. Immunotherapy targeting NK cell may enhance the therapeutic efficacy of current immunother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hansol, Da Silva, Inês Pires, Palendira, Umaimainthan, Scolyer, Richard A., Long, Georgina V., Wilmott, James S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002669/ https://www.ncbi.nlm.nih.gov/pubmed/33802954 http://dx.doi.org/10.3390/cancers13061363

Ejemplares similares

Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome
por: Attrill, Grace H., et al.
Publicado: (2022)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
por: Conway, Jordan W., et al.
Publicado: (2022)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
por: Quek, Camelia, et al.
Publicado: (2021)

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes
por: Shteinman, Eva R., et al.
Publicado: (2022)

Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
por: Nahar, Kazi J., et al.
Publicado: (2022)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma
por: Haas, Lisa, et al.
Publicado: (2021)

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
por: Mao, Yizhe, et al.
Publicado: (2023)

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis
por: Krisp, Christoph, et al.
Publicado: (2018)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Melanoma progression is associated with NK cell exhaustion
por: Pires da Silva, Ines, et al.
Publicado: (2014)

Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma
por: Yaseen, Zarwa, et al.
Publicado: (2022)

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas
por: Quek, Camelia, et al.
Publicado: (2019)

Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism
por: Thomas, Olivia G, et al.
Publicado: (2023)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Navigating the cellular landscape in tissue: Recent advances in defining the pathogenesis of human disease
por: Chen, Helen Y., et al.
Publicado: (2022)

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
por: Conway, Jordan W, et al.
Publicado: (2022)

Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas
por: Silva, Inês Pires da, et al.
Publicado: (2018)

Human immunity against EBV—lessons from the clinic
por: Tangye, Stuart G., et al.
Publicado: (2017)

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors
por: Ziemys, Arturas, et al.
Publicado: (2020)

Memory-like Differentiation Enhances NK Cell Responses to Melanoma
por: Marin, Nancy D., et al.
Publicado: (2021)

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
por: Shklovskaya, Elena, et al.
Publicado: (2020)

Expression of NGF/proNGF and Their Receptors TrkA, p75(NTR) and Sortilin in Melanoma
por: Marsland, Mark, et al.
Publicado: (2022)

Spatial mapping reveals granuloma diversity and histopathological superstructure in human tuberculosis
por: Sawyer, Andrew J., et al.
Publicado: (2023)

Cytotoxic CD8+ T cells and tissue resident memory cells in colorectal cancer based on microsatellite instability and BRAF status
por: Toh, James Wei Tatt, et al.
Publicado: (2021)

CXCR3 Provides a Competitive Advantage for Retention of Mycobacterium tuberculosis-Specific Tissue-Resident Memory T Cells Following a Mucosal Tuberculosis Vaccine
por: Armitage, Ellis, et al.
Publicado: (2023)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
por: Lim, Su Yin, et al.
Publicado: (2017)

NK Cells as Potential Targets for Immunotherapy in Endometriosis
por: Ścieżyńska, Aneta, et al.
Publicado: (2019)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
por: Park, John J., et al.
Publicado: (2021)

Small-Cell Lung Cancer—An Update on Targeted and Immunotherapies
por: McNamee, Nicholas, et al.
Publicado: (2023)

Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications
por: Kiyohara, Eiji, et al.
Publicado: (2015)

Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy
por: Islam, Rasa, et al.
Publicado: (2021)

Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma
por: Marsh-Wakefield, Felix, et al.
Publicado: (2022)

Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value
por: Barnhill, Raymond, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1u8sen0k7sdfce58vhoudriq11